Valuation: EnteroMedics Inc

Market Cap 10.74M 9.76M 9.01M 8.14M 15.37M 1.01B 15.91M 108M 42.95M 541M 40.29M 39.44M 1.71B P/E 2026 *
-3x
P/E 2027 * -1.94x
Enterprise Value 10.74M 9.76M 9.01M 8.14M 15.37M 1.01B 15.91M 108M 42.95M 541M 40.29M 39.44M 1.71B EV / Sales 2026 *
104x
EV / Sales 2027 * 53.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 103K 93.58K 86.46K 78.1K 147K 9.67M 153K 1.04M 412K 5.19M 386K 378K 16.44M 200K 182K 168K 152K 286K 18.78M 296K 2.02M 800K 10.08M 750K 735K 31.92M
Net income -4.49M -4.08M -3.77M -3.4M -6.42M -421M -6.65M -45.31M -17.95M -226M -16.84M -16.49M -716M -7.85M -7.13M -6.59M -5.95M -11.23M -737M -11.62M -79.2M -31.38M -395M -29.44M -28.82M -1.25B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-